We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newly Identified Protein Biomarkers in Blood Predict Sudden Cardiac Arrest Before it Strikes

By LabMedica International staff writers
Posted on 27 Jan 2023
Print article
Image: A novel research study moves the needle on predicting sudden cardiac arrest (Photo courtesy of Pexels)
Image: A novel research study moves the needle on predicting sudden cardiac arrest (Photo courtesy of Pexels)

Sudden cardiac arrest, or the sudden loss of heartbeat, is a life-threatening heart condition and often fatal. Despite providing an organized emergency medical response, less than 10% of individuals having a cardiac arrest will survive. Hence, there is a need for risk determination, early prediction, and improved primary prevention of sudden cardiac arrest. Now, researchers have identified a panel of novel blood biomarkers specifically associated with sudden cardiac arrest. These biomarkers have the potential to enhance the clinical prediction of sudden cardiac arrest.

In a collaborative study, investigators at Cedars-Sinai (Los Angeles, CA, USA) analyzed a number of blood biomarkers obtained from survivors of sudden cardiac arrest. They compared the results from one cohort of people without coronary artery disease and one cohort with the disease. The researchers identified 26 protein biomarkers associated with sudden cardiac arrest that could improve the prediction of this life-threatening heart condition.

“We identified a total of 26 protein biomarkers associated with sudden cardiac arrest when cases were compared to controls, of which, 20 differentiated sudden cardiac arrest from coronary artery disease,” said Faye Norby, PhD, a research scientist at the Center for Cardiac Arrest Prevention in the Smidt Heart Institute and first author of the study. “While these biomarkers have the potential to enhance prediction of sudden cardiac arrest, future studies are needed to replicate these findings in a larger group of patients.”

Related Links:
Cedars-Sinai 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.